Bayer Pharma Aktiengesellschaft

Piramal Imaging Sa

Bayer Aktiengesellschaft

Bayer Pharma Aktiengessellschaft

Deutsches Krebsforschungszentrum Stiftung Des Offentlichen Rechts

Holger Siebeneicher

Holger Steuber

Ulf Bömer

Ulrich Bothe

Judith Günther

Martin Lange

Sven Ring

Roland Neuhaus

Christian Stegmann

Peter Hauff

Hartmut Rehwinkel

Katja Zimmermann

Wolfgang Schwede

Duy Nguyen

Marcus Bauser

Sonja Anlauf

Olaf Panknin

Stefan Kaulfuss

Markus Berger

Andrea Rotgeri

Marcus Koppitz

Martin Kruger

Nicholas Charles Ray

Martina Schäfer

Benjamin Bader

Antje Margret Wengner

Reinhard Nubbemeyer

Nicole Schmidt

Alexandra Rausch

Andreas Sutter

Christian Friedrich

Jessica Lohrke

Horst Irlbacher

Paul Matthew Blaney

Elisabeth Pook

Jens Nagel

Keith Graham

Nico Bräuer

Adam James Davenport

Mathias Berndt

Antonius Ter Laak

Oliver Martin Fischer

Ildiko Terebesi

Antje Rottmann

Martin Krüger

Hana Cernecka

Shelley Anne Parrott

Michael Reinhardt

Michaele Peters

James Lindsay Carr

Pascal Savy

Gernot Langer

Andrea Wagenfeld

Robert James Townsend

Nina Connelly Ursinyova

Katrin Nowak-reppel

Frank Sacher

Sabine Pilari

Andreas Von Deimling

Martina Schafer

Judith Gunther

Stefan Pusch

Ondozabal Hideki Miyatake

The present application relates to novel substituted indazoles, to processes for preparation thereof, to the use thereof alone or in combinations for treatment and/or prophylaxis of diseases, and to the use thereof for production of medicaments for treatment and/or prophylaxis of diseases, especially for treatment and/or prophylaxis of endometriosis and endometriosis-associated pain and other endometriosis-associated symptoms such as dysmenorrhoea, dyspareunia, dysuria and dyschezia, of lymphoma, rheumatoid arthritis, spondyloarthritis (especially psoriatic spondyloarthritis and Bekhterev's disease), lupus erythematosus, multiple sclerosis, macular degeneration, COPD, gout, fatty liver disorders, insulin resistance, neoplastic disorders and psoriasis.

Substituted indazoles, methods for the production thereof, pharmaceutical preparations that contain said substituted indazoles, and use of said substituted indazoles to produce drugs

The present invention covers substituted. Pyrazolo-pyrrolo-pyrimidine-dione (PPPD) compounds of general formula (I): in which R, Rand Rare as defined herein, methods of preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of neurogenic diseases, as a sole agent or in combination with other active ingredients. 

Pyrazolo-pyrrolo-pyrimidine-dione derivatives as P2X3 inhibitors

Substituted indazoles, methods for the production thereof, pharmaceutical preparations that contain said new substituted indazoles, and use of said new substituted indazoles to produce drugs

The present invention relates to benzimidazol-2-amines of general formula (I), in which R, R, R, R, R, R, R, R, R, R, Rand Rare as defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of neoplasms, as a sole agent or in combination with other active ingredients.

Benzimidazol-2-amines as mIDH1 inhibitors

2-substituted indazoles, methods for producing same, pharmaceutical preparations that contain same, and use of same to produce drugs

The present invention covers [8-(phenylsulfonyl)-3,8-diazabicyclo[3.2.1]oct-3-yl](1H-1,2,3-triazol-4-yl)methanone compounds of general formula (I): in which R, R, R, Rand Rare as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of disorders, in particular of gynecological disorders, hyperproliferative disorders, metabolic disorders, or inflammatory disorders as a sole agent or in combination with other active ingredients.

[8-(phenylsulfonyl)-3,8-diazabicyclo[3.2.1]oct-3-yl](1H-1,2,3-triazol-4-yl)methanones

The present invention relates to benzimidazol-2-amines of general formula (I), in which R, R, R, R, R, R, R, R, R, R, Rand Rare as defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of neoplasms, as a sole agent or in combination with other active ingredients. 

The present invention relates to benzimidazol-2-amines of general formula (I): in which R, R, R, R, R, R, R, R, R, R, Rand Rare as defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of neoplasms, as a sole agent or in combination with other active ingredients. 

Benzimidazol-2-amines as MIDH1 inhibitors

The present application relates to novel 6-substituted indazoles having a carboxamide side chain, to processes for their preparation, to their use alone or in combinations for the treatment and/or prophylaxis of diseases, and to their use for producing medicaments for the treatment and/or prophylaxis of diseases, in particular for the treatment and/or prophylaxis of endometriosis, lymphomas, macular degeneration, COPD and psoriasis.

Indazolecarboxamides, processes for their preparation, pharmaceutical preparations comprising them and their use for producing medicaments

The present invention relates to novel fluorine containing compounds, methods for their preparation, the intermediates of the synthesis, their use as diagnostic agents, especially for imaging of thrombi. The invention relates to positron emission tomography (PET) agents and associated precursor reagents, and methods for producing such radiolaveled agents for imaging of thrombi in a mammalian body. More particularly, the invention relates to small nonpeptide, high-affinity, specific-binding glycoprotein IIb/IIIa antagonists for imaging of thrombi.

Compounds for binding to the platelet specific glycoprotein IIb/IIIa and their use for imaging of thrombi

The present invention relates to novel fluorine containing compounds, methods for their preparation, the intermediates of the synthesis, their use as diagnostic agents, especially for imaging of thrombi. The invention relates to positron emission tomography (PET) agents and associated precursor reagents, and methods for producing such radiolaveled agents for imaging of thrombi in a mammalian body. More particularly, the invention relates to small nonpeptide, high-affinity, specific-binding glycoprotein 11b/IIIa antagonists for imaging of thrombi.

Compounds for binding to the platelet specific glycoprotein IIB/IIIA and their use for imaging of thrombi

The invention relates to a process for the production of radiotracers. In particular, this invention relates the isolation of radiotracers with containers filled with a stationary phase.

Usage of low to medium-pressure liquid chromatography for the purification of radiotracers

Growing community of inventors

Berlin, Germany

Holger Siebeneicher